Literature DB >> 9218752

Development of insulitis and diabetes in B cell-deficient NOD mice.

M Yang1, B Charlton, A M Gautam.   

Abstract

Insulin-dependent diabetes mellitus (IDDM) is believed to be an autoimmune disease that results from autoimmune destruction of the insulin-secreting beta-cells of the pancreas. In addition to a lymphocytic infiltration (insulitis) of the islets, patients with IDDM have autoantibodies directed against the components of the islet cells. Several beta-cell proteins have been identified as candidate autoantigens. The non-obese diabetic (NOD) mouse is a murine model for spontaneous IDDM. It is generally accepted that IDDM in patients and NOD mice results from the T lymphocyte-mediated destruction of beta-cells. However, the direct role of B lymphocytes in the disease process has not yet been clarified. To test directly the role of B cells in IDDM, we have generated B cell-deficient NOD mice by backcrossing the microMT-/- B cell 'knockout mice' onto the NOD background. The mice had no evidence of functional B cells as determined by flow cytometry and antibody production. We show that two out of seven of these mice developed insulitis and diabetes. These results suggest that despite an absence of B cells some NOD mice can still develop insulitis and diabetes.

Entities:  

Mesh:

Year:  1997        PMID: 9218752     DOI: 10.1006/jaut.1997.0128

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  21 in total

1.  Regulation of B lymphocyte responses to Toll-like receptor ligand binding during diabetes prevention in non-obese diabetic (NOD) mice.

Authors:  Christopher S Wilson; Sydney K Elizer; Andrew F Marshall; Blair T Stocks; Daniel J Moore
Journal:  J Diabetes       Date:  2015-03-03       Impact factor: 4.006

2.  The CD19 signalling molecule is elevated in NOD mice and controls type 1 diabetes development.

Authors:  Alexandra I Ziegler; Melanie A Le Page; Mhairi J Maxwell; Jessica Stolp; Haoyao Guo; Abhirup Jayasimhan; Margaret L Hibbs; Pere Santamaria; Jacques F Miller; Magdalena Plebanski; Pablo A Silveira; Robyn M Slattery
Journal:  Diabetologia       Date:  2013-09-08       Impact factor: 10.122

3.  Alpha4beta7 integrin/MAdCAM-1 adhesion pathway is crucial for B cell migration into pancreatic lymph nodes in nonobese diabetic mice.

Authors:  Baohui Xu; Rachel E Cook; Sara A Michie
Journal:  J Autoimmun       Date:  2010-05-21       Impact factor: 7.094

Review 4.  Mouse models for the study of autoimmune type 1 diabetes: a NOD to similarities and differences to human disease.

Authors:  John P Driver; David V Serreze; Yi-Guang Chen
Journal:  Semin Immunopathol       Date:  2010-04-28       Impact factor: 9.623

5.  Increased expression of TACI on NOD B cells results in germinal centre reaction anomalies, enhanced plasma cell differentiation and immunoglobulin production.

Authors:  Viqar S Banday; Radha Thyagarajan; Mia Sundström; Kristina Lejon
Journal:  Immunology       Date:  2016-08-23       Impact factor: 7.397

6.  B cells in autoimmune diabetes.

Authors:  F Susan Wong; Li Wen
Journal:  Rev Diabet Stud       Date:  2005-11-10

Review 7.  Teplizumab therapy for type 1 diabetes.

Authors:  Umesh B Masharani; Joseph Becker
Journal:  Expert Opin Biol Ther       Date:  2010-03       Impact factor: 4.388

Review 8.  B cells and type 1 diabetes ...in mice and men.

Authors:  Rochelle M Hinman; Mia J Smith; John C Cambier
Journal:  Immunol Lett       Date:  2014-01-25       Impact factor: 3.685

9.  Transfer of human serum IgG to nonobese diabetic Igmu null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjögren's syndrome.

Authors:  C P Robinson; J Brayer; S Yamachika; T R Esch; A B Peck; C A Stewart; E Peen; R Jonsson; M G Humphreys-Beher
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

10.  Accounting for chance in the calculus of autoimmune disease.

Authors:  Daniel J Moore
Journal:  Med Hypotheses       Date:  2009-10-01       Impact factor: 1.538

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.